AzTrials
AzTrials

HIVPhase 3NCT01818596

Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment

A Phase 3 study testing E/C/F/TAF in people with HIV and HIV Infections, run by Gilead Sciences at 70 sites in 9 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The primary objective of this study is to evaluate the effect of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) tablet on renal parameters at Week 24 in treatment-naive and treatment-experienced HIV-positive, adults with mild to moderate renal impairment. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
HIV, HIV Infections
What is being tested?
E/C/F/TAF
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
252 participants
Where
70 sitesin 9 countries
Study dates
27 Mar 2013to 18 Jul 2018
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Cohort 1 (treatment-experienced switch)
  • Must not have a history of known resistance to elvitegravir (EVG), tenofovir disoproxil fumarate (TDF), or emtricitabine (FTC)
  • Plasma HIV-1 RNA concentrations (at least two measurements) at undetectable levels (according to the local assay being used) in the 6 months preceding the screening visit and have HIV-1 RNA < 50 copies/mL at screening
  • Estimated glomerular filtration rate (GFR) 30-69 mL/min according to the Cockcroft-Gault formula for creatinine clearance, using actual weight
  • May be currently enrolled in Gilead studies GS-US-236-0102, GS-US-236-0103, and GS-US-216-0114, but will be eligible to enroll only after the Week 144 visit for that study is complete; or currently receiving Stribild® (STB) or atazanavir (ATV)/cobicistat (COBI) + Truvada (TVD) in Gilead studies GS-US-236-0104 or GS-US-216-0105, but will be eligible to enroll only after the Week 48 visit for that study is complete.
  • Cohort 2 (treatment-naive)
Show all 24Show fewer
  • Plasma HIV-1 RNA levels ≥ 1,000 copies/mL at screening
  • Screening genotype report provided by Gilead Sciences must show sensitivity to EVG, FTC, and TDF
  • No prior use of any approved or investigational antiretroviral drug for any length of time, except the use for pre-exposure prophylaxis (PrEP), or post-exposure prophylaxis (PEP), up to 6 months prior to screening
  • Estimated GFR 30-69 mL/min according to the Cockcroft Gault formula for creatinine clearance, using actual weight
  • All Cohorts:
  • All individuals must meet all of the following inclusion criteria to be eligible for participation in this study:
  • The ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
  • CD4+ count of ≥ 50 cells/μL
  • Stable renal function: serum creatinine measurements to be taken at least once (within three months of screening)
  • Cause of underlying chronic kidney disease (eg hypertension, diabetes) stable, without change in medical management, for 3 months prior to baseline
  • Normal electrocardiogram (ECG)
  • Hepatic transaminases (AST and ALT) ≤ 5 x upper limit of normal (ULN)
  • Total bilirubin ≤ 1.5 mg/dL, or normal direct bilirubin
  • Adequate hematologic function
  • Serum amylase ≤ 5 x ULN
  • Females of childbearing potential must agree to utilize highly effective contraception methods (two separate forms of contraception, one of which must be an effective barrier method, or be non-heterosexually active, practice sexual abstinence) from screening throughout the duration of study treatment and for 30 days following the last dose of study drug
  • Females who utilize hormonal contraceptive as one of their birth control methods must have used the same method for at least three months prior to study dosing
  • Males must agree to utilize a highly effective method of contraception during heterosexual intercourse throughout the study period and for 30 days following discontinuation of investigational medicinal product. A highly effective method of contraception is defined as two separate forms of contraception, one of which must be an effective barrier method, or males must be non-heterosexually active, or practice sexual abstinence

Who cannot join

  • A new AIDS-defining condition (excluding CD4 cell count and percentage criteria) diagnosed within the 30 days prior to screening,with the exception of the first two bullet points
  • Hepatitis C virus (HCV) antibody positive. Individuals who are HCV positive, but have a documented negative HCV RNA, are eligible
  • Hepatitis B surface antigen (HBVsAg) positive
  • Individuals receiving drug treatment for Hepatitis C, or individuals who are anticipated to receive treatment for Hepatitis C during the course of the study
  • Individuals experiencing decompensated cirrhosis (eg, ascites, encephalopathy, etc.)
  • Females who are breastfeeding
Show all 14Show fewer
  • Positive serum pregnancy test
  • Have an implanted defibrillator or pacemaker
  • Current alcohol or substance use judged by the Investigator to potentially interfere with study compliance
  • A history of malignancy within the past 5 years or ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous carcinoma
  • Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to baseline
  • Individuals on hemodialysis, other forms of renal replacement therapy, or on treatment for underlying kidney diseases (including prednisolone and dexamethasone)
  • Individuals receiving ongoing therapy with any medications not to be used with EVG, COBI, FTC, or TAF or individuals with any known allergies to the excipients of E/C/F/TAF
  • Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Trial locations and contacts

70 sites in 9 countries.

70 sites in 9 countries

United States51 sites

  • Albany Medical College

    Albany, New York, 12208

  • Upstate Infectious Diseases Associates

    Albany, New York, 12208

  • University of Colorado

    Aurora, Colorado, 80045

  • St. Hope Foundation

    Bellaire, Texas, 77401

  • Be Well Medical Center, P.C.

    Berkley, Michigan, 48210

  • Pacific Oaks Medical Group

    Beverly Hills, California, 90211

  • Community Research Initiative of New England

    Boston, Massachusetts, 02111

  • University of Cincinnati

    Cincinnati, Ohio, 45267-0405

  • MetroHealth Medical Center

    Cleveland, Ohio, 44109

  • North Texas Infectious Diseases Consultants, PA

    Dallas, Texas, 75246

  • Infectious Disease Specialists of Atlanta

    Decatur, Georgia, 30033

  • National Jewish Health

    Denver, Colorado, 80206

  • Henry Ford Health System

    Detroit, Michigan, 48202

  • Gary J. Richmond, MD PA

    Fort Lauderdale, Florida, 33316

  • Midway Immunology and Research Center

    Ft. Pierce, Florida, 34982

  • Garcias' Family Health Group

    Harlingen, Texas, 78550

  • Kaiser Permanente

    Hayward, California, 94545

  • Therapeutic Concepts, PA

    Houston, Texas, 77004

  • Gordon E. Crofoot MD, PA

    Houston, Texas, 77098

  • Indiana University School of Medicine

    Indianapolis, Indiana, 46202

  • The Kansas City Care Clinic (KC Free Health Clinic)

    Kansas City, Missouri, 64111

  • Health for Life Clinic PLLC

    Little Rock, Arkansas, 72207

  • Long Beach Education and Research Consultants

    Long Beach, California, 90813

  • LA Gay & Lesbian Center - Jeffrey Goodman Special Care Clinic

    Los Angeles, California, 90028

  • Peter J Ruane, MD, Inc

    Los Angeles, California, 90036

  • Anthony Mills MD, Inc

    Los Angeles, California, 90069

  • Mercer University

    Macon, Georgia, 31210

  • North Shore University Hospital/Division of Infectious Diseases

    Manhasset, New York, 11030

  • Hennepin County Medical Center

    Minneapolis, Minnesota, 55415

  • Jersey Shore University Medical Center

    Neptune City, New Jersey, 07754

  • Saint Michael's Medical Center

    Newark, New Jersey, 07102

  • Idocf/Valuhealthmd

    Orlando, Florida, 32806

  • Desert Medical Group Inc. dba Desert Oasis Healthcare Medical Group

    Palm Springs, California, 92262

  • University of PA HIV Clinical Trials Unit

    Philadelphia, Pennsylvania, 19104

  • Thomas Jefferson University

    Philadelphia, Pennsylvania, 19107

  • Maricopa Integrated Health System - McDowell Clinic

    Phoenix, Arizona, 85006

  • Pueblo Family Physicians

    Phoenix, Arizona, 85015

  • Aids Care

    Rochester, New York, 14607

  • Kaiser Permanente Medical Group

    Sacramento, California, 95825

  • Metropolis Medical

    San Francisco, California, 94109

  • Kaiser Permanente CTU San Francisco

    San Francisco, California, 94118

  • Southwest CARE Center

    Santa Fe, New Mexico, 87505

  • Peter Shalit, MD

    Seattle, Washington, 98104

  • The Research Institute

    Springfield, Massachusetts, 01105

  • Southampton Healthcare, Inc.

    St Louis, Missouri, 63139

  • University of South Florida

    Tampa, Florida, 33602

  • Jacobi Medical Center

    The Bronx, New York, 10461

  • Montefiore Medical Center

    The Bronx, New York, 10467

  • Dupont Circle Physician's Group

    Washington D.C., District of Columbia, 20009

  • Triple O Research Institute, P.A.

    West Palm Beach, Florida, 33401

  • Rowan Tree Medical, P.A.

    Wilton Manors, Florida, 33305

Other trials in United States

Thailand4 sites

  • HIV-NAT, Thai Red Cross AIDS Research Centre

    Bangkok, 10330

  • Faculty of Medicine Ramathibodi Hospital, Mahidol University

    Bangkok, 10400

  • Department of Preventive and Social Medicine, Faculty of Medicine, Siriraj Hospital

    Bangkok, 10700

  • Srinagarind Hospital, Khon Kaen University

    Khon Kaen, 40002

Other trials in Thailand

United Kingdom4 sites

  • Brighton & Sussex University Hospitals NHS Trust

    Brighton, BN2 1ES

  • Kings College London

    London, SE5 9RJ

  • Chelsea and Westminster NHS Foundation Trust Hospital

    London, Sw10 9NH

  • Central Manchester University Hospitals NHS foundation Trust

    Manchester, M13 0FH

Other trials in United Kingdom

Australia3 sites

  • Holdsworth House Medical Practice

    Darlinghurst, New South Wales, 2010

  • Clinical Research Infectious Diseases Department- Alfred Hospital

    Melbourne, Victoria, 3004

  • Prahran Market Clinic

    Prahran, Victoria, 3181

Other trials in Australia

Spain3 sites

  • Hospital Universitari de Bellvitge

    Barcelona, 8907

  • Germans Trias i Pujol University Hospital

    Barcelona, 8916

  • Hospital La Paz

    Madrid, 28046

Other trials in Spain

France2 sites

  • Hopital de la Croix Rousse

    Lyon, 69004

  • GHPS Service des maladies infectieuses et tropicales pavillon Laveran unité de recherche clinique

    Paris, 75651

Other trials in France

Dominican Republic1 site

  • Instituto Dominicano de Estudios Virologicos (IDEV)

    Santo Domingo, 99999

Other trials in Dominican Republic

Mexico1 site

  • Hospital Civil de Guadalajara Dr. Juan I. Menchaca

    Guadalajara, Jalisco, 44340

Other trials in Mexico

Netherlands1 site

  • University Medical Center Utrecht

    Utrecht, 3584 CX

Other trials in Netherlands

About this study

Official title: A Phase 3 Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients With Mild to Moderate Renal Impairment

The primary objective of this study is to evaluate the effect of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) tablet on renal parameters at Week 24 in treatment-naive and treatment-experienced HIV-positive, adults with mild to moderate renal impairment.

Conditions
HIV, HIV Infections
Being tested
E/C/F/TAF
Keywords
HIV, HIV-1 Infected, Treatment Experienced, Treatment Naive
Medical subject headings
HIV Infections

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • E/C/F/TAFDrug

    Also called Genvoya®

    E/C/F/TAF (150/150/200/10 mg) FDC tablet administered orally once daily with food

Study groups in NCT01818596
Study groupRoleWhat they receive
E/C/F/TAFExperimentalParticipants will receive E/C/F/TAF for 144 weeks. Following Week 144, in countries where E/C/F/TAF is not available (except for the United Kingdom), participants will be given the option to continue in the study and receive E/C/F/TAF for another 48 weeks, or until the product becomes available through an access program, or until Gilead Sciences elects to discontinue the study in that country, whichever comes first.
Receives: Drug: E/C/F/TAF

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline in the Estimated Glomerular Filtration Rate Calculated by the Cockcroft-Gault Formula (eGFR_CG) at Week 24

    eGFR is a measurement of the kidney's ability to filter blood.

    Measured: Baseline; Week 24

  2. Change From Baseline in eGFR Calculated by the Chronic Kidney Disease Epidemiology Collaboration Method Based on Cystatin C (eGFR_CKD-EPI,cysC) at Week 24

    eGFR is a measurement of the kidney's ability to filter blood. The eGFR_CKD-EPI,cysC method is adjusted for age and sex.

    Measured: Baseline; Week 24

  3. Change From Baseline in eGFR Calculated by the CKD-EPI Method Based on Serum Creatinine (eGFR_CKD-EPI,Creatinine) at Week 24

    eGFR is a measurement of the kidney's ability to filter blood. The eGFR_CKD-EPI,creatinine method is adjusted for age, race, and sex.

    Measured: Baseline; Week 24

Secondary outcomes (18)

  1. Change From Baseline in Actual GFR (aGFR) of E/C/F/TAF for Participants Enrolled in the PK/PD Substudy

    aGFR was directly measured using iohexol plasma clearance (CLiohexol).

    Measured: Baseline; Week 2, 4, or 8; Week 24

  2. Percent Change From Baseline in C-type Collagen Sequence (CTX) at Weeks 24 and 48

    CTX is a biomarker of bone turnover.

    Measured: Baseline; Weeks 24 and 48

  3. Percent Change From Baseline in Procollagen Type 1 N-terminal Propeptide (P1NP) at Weeks 24 and 48

    P1NP is a biomarker of bone turnover.

    Measured: Baseline; Weeks 24 and 48

  4. Percent Change From Baseline in Retinol Binding Protein (RBP) to Creatinine Ratio (μg/g) at Weeks 24, 48, 96, and 144

    Urine RBP is a renal biomarker which is used to evaluate drug-induced kidney injury.

    Measured: Baseline; Weeks 24, 48, 96, and 144

  5. Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio (μg/g) at Weeks 24, 48, 96, and 144

    Urine beta-2-microglobulin is a renal biomarker which is used to evaluate drug-induced kidney injury.

    Measured: Baseline; Weeks 24, 48, 96, and 144

  6. Percentage of Participants Experiencing Adverse Events or Graded Laboratory Abnormalities

    Adverse events (AEs) and graded laboratory abnormalities occurring during the E/C/F/TAF treatment period were summarized across the participant population. A participant was counted once if they had a qualifying event.

    Measured: Baseline up to Week 240 plus 30 days

  7. Percentage of Participants Achieving HIV-1 RNA < 50 Copies/mL at Weeks 24, 48, 96, and 144

    The percentage of participants achieving HIV-1 RNA < 50 Copies/mL at Weeks 24, 48, 96, and 144 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Measured: Weeks 24, 48, 96, and 144

  8. Pharmacokinetic (PK) Parameter: Cmax of TAF

    Cmax is defined as the maximum concentration of drug. Blood draws for this outcome may have been at the Week 2, 4, or 8 visit.

    Measured: Predose, and 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose

  9. PK Parameter: Tmax of TAF

    Tmax is defined as the time of Cmax. Blood draws for this outcome may have been at the Week 2, 4, or 8 visit.

    Measured: Predose, and 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose

  10. PK Parameter: Clast of TAF

    Clast is defined as the last observable concentration of drug. Blood draws for this outcome may have been at the Week 2, 4, or 8 visit.

    Measured: Predose, and 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose

  11. PK Parameter: Tlast of TAF

    Tlast is defined as the time of Clast. Blood draws for this outcome may have been at the Week 2, 4, or 8 visit.

    Measured: Predose, and 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose

  12. PK Parameter: λz of TAF

    λz is defined as the terminal elimination rate constant. Blood draws for this outcome may have been at the Week 2, 4, or 8 visit.

    Measured: Predose, and 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose

  13. PK Parameter: AUCtau of TAF

    AUCtau is defined as the concentration of drug over time (area under the plasma concentration versus time curve over the dosing interval). Blood draws for this outcome may have been at the Week 2, 4, or 8 visit.

    Measured: Predose, and 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose

  14. PK Parameter: t1/2 of TAF

    t1/2 is defined as the estimate of the terminal elimination half-life of the drug. Blood draws for this outcome may have been at the Week 2, 4, or 8 visit.

    Measured: Predose, and 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose

  15. PK Parameter: AUCtau of Tenofovir Diphosphate (TFV-DP) in Peripheral Blood Mononuclear Cell (PBMC) for Participants Enrolled in PK/PD Sub-study

    TFV-DP is an active phosphorylated metabolite of tenofovir alafenamide. AUCtau is defined as the concentration of drug over time (area under the plasma concentration versus time curve over the dosing interval). Blood draws for this outcome may have been at the Week 2, 4, or 8 visit.

    Measured: Predose, and 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose

  16. Change From Baseline in the eGFR_CG at Weeks 48, 96, and 144

    eGFR is a measurement of the kidney's ability to filter blood.

    Measured: Baseline; Weeks 48, 96, and 144

  17. Change From Baseline in eGFR_CKD-EPI,cysC at Weeks 48, 96, and 144

    eGFR is a measurement of the kidney's ability to filter blood. The eGFR_CKD-EPI,cysC method is adjusted for age and sex.

    Measured: Baseline; Weeks 48, 96, and 144

  18. Change From Baseline in eGFR_CKD-EPI,Creatinine at Weeks 48, 96, and 144

    eGFR is a measurement of the kidney's ability to filter blood. The eGFR_CKD-EPI,creatinine method is adjusted for age, race, and sex.

    Measured: Baseline; Weeks 48, 96, and 144

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Mar 2013 (estimated)
  2. Study start27 Mar 2013
  3. Primary completion31 Jul 2014
  4. Study completion18 Jul 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
252 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01818596
Sponsor's protocol ID
GS-US-292-0112
Other IDs
2013-000516-25
Status last verified
Jun 2019
First submitted
22 Mar 2013
Last updated
2 Mar 2020
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.

Publications

  • Pozniak A, Arribas JR, Gathe J, Gupta SK, Post FA, Bloch M, Avihingsanon A, Crofoot G, Benson P, Lichtenstein K, Ramgopal M, Chetchotisakd P, Custodio JM, Abram ME, Wei X, Cheng A, McCallister S, SenGupta D, Fordyce MW; GS-US-292-0112 Study Team. Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study. J Acquir Immune Defic Syndr. 2016 Apr 15;71(5):530-7. doi: 10.1097/QAI.0000000000000908.

    PubMed 26627107

  • Post FA, Tebas P, Clarke A, Cotte L, Short WR, Abram ME, Jiang S, Cheng A, Das M, Fordyce MW. Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study. J Acquir Immune Defic Syndr. 2017 Feb 1;74(2):180-184. doi: 10.1097/QAI.0000000000001186.

    PubMed 27673443

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing E/C/F/TAF in people with HIV and HIV Infections, run by Gilead Sciences at 70 sites in 9 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 24 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 2 Mar 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 70 sites in United States, Thailand, United Kingdom, Australia, Spain and 4 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 18 Feb 2016). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline in the Estimated Glomerular Filtration Rate Calculated by the Cockcroft-Gault Formula (eGFR_CG) at Week 24 (time frame: Baseline; Week 24). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01818596, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Mar 2020.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in